USD/SGD: Rebound risk after Hormuz setback – OCBC
OCBC strategists Sim Moh Siong and Christopher Wong note USD/SGD rebounded sharply after Iran reclosed the Strait of Hormuz, reversing Friday’s drop to 1.2667. While daily momentum remains bearish, RSI is turning up from oversold, with key support at 1.2700 and 1.2670 and resistance at 1.2750/60, 1.2800 and 1.2850. Focus stays on whether parties reach a deal or escalate militarily in coming days.
Safe-haven bid lifts pair off lows
"USD/SGD had traded as low as 1.2667 last Fri, on news of conditional open of passageway at strait of Hormuz."
"But the pair rebounded sharply this morning in early trade following the weekend setback – reclosure of the strait."
"Focus remains on whether both parties manage to get a deal or if there are further military escalation in the next 24-48 hours."
"Bearish momentum on daily chart intact but shows tentative signs of fading while RSI shows signs of rising from near oversold conditions."
"Key support at 1.27, 1.2670 (76.4% fibo). Resistance at 1.2750/60 levels (50 DMA, 50% fibo), 1.28 levels (21, 100 DMAs, 38.2% fibo retracement of 2026 low to high), 1.2850 (200 DMA, 23.6% fibo)."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
